Alkermes' Depression Drug Likely Needs Another Trial After Crushing US Advisory Cmte. Vote
Executive Summary
Nearly every panelist cited lack of substantial evidence of efficacy in voting against approval of ALKS 5461, a fixed-dose combination of buprenorphine and samidorphan.